Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Nutritional and Metabolic Diseases

Nervous System Diseases

Syndrome

Urinary Bladder Neoplasms

Malnutrition

Pain

Urinary Bladder, Neurogenic

Endometriosis

Urinary Bladder Diseases

Cystitis

Cystitis, Interstitial

Cystitis, Hemorrhagic

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Diseases

Male Urogenital Diseases

Genital Diseases, Female

Genital Diseases

Neurologic Manifestations

Seven days of preoperative oral supplementation with an immune-enhanced oral nutrition

Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.

IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag

Immunonutrition

Ilaria Lucca, MD

François Crettenand, MD

Bernhard Kiss, MD

Thomas Tawadros, PhD

The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.

As a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.

This is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.

Despite standardized surgical technique and the development of new perioperative care protocols, cystectomy morbidity remains a serious challenge for urologists. Most common postoperative complications, such as infections, often lead to longer length of stay and worse survival. Malnutrition has been identified as an independent and modifiable risk factor for both mortality and morbidity. Immunonutrition (IN), containing arginine, ribonucleic acid and omega-3 polyunsaturated fatty acids, aims to improve the nutritional status, immunological function and clinical outcome of surgical patients. Meta-analyses have demonstrated that preoperative IN reduces complications and length of hospital stay after major bowel surgery. Evidence-based data on preoperative oral IN support for cystectomy patients are lacking, which does not allow this treatment to be widely accepted, recommended, or reimbursed by health insurances in most European countries. Uncertainties also remain about the exact mechanism by which IN modulates the host immune response.

Complication rates after cystectomy range from 40-75%. Malnutrition has been identified as an independent and modifiable risk factor for both mortality and morbidity. To date, and in the last 20 years, no single intervention has allowed for a significant reduction in morbidity after cystectomy, which remains one of the highest in surgery. The present adequately powered multicenter RCT has the potential of changing current practice by recommending preoperative IN before cystectomy in case of positive results. If the present RCT demonstrates a benefit in administrating IN prior to cystectomy, urological guidelines will be modified accordingly to this new evidence. IN will then be recommended before cystectomy for the patient's benefit. The investigators truly believe that the proposed study is of high clinical importance with potential impact on perioperative urology guidelines.

Multicenter, prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)

Long term overall and cancer-specific survival for bladder cancer patients

Assessment of the quality of life after surgery through a questionnaire (EORTC QLQ-C30)

Identification of biomarkers predictive of postoperative complications studying the patient's immune and microbiome signature: analysis of immune cells in the blood, analysis of the polyfunctionality of blood T cells, analysis of immune-related proteins in the urine and serum, microbiota analysis, expression of Argininosuccinate synthetase 1

Determination of infectious complications rate at 30 days after surgery (pneumonia, urinary tract infection, surgical site infection, sepsis, shock).

Determination of the Comprehensive Complication Index (CCI) at 30 and 90 days after surgery. The range is between 0 (no complication) to 100 (death).

Determination of the mortality rate at 30 and 90 days after surgery

Determination of the post-operative complication-free survival

Serum arginine levels will be assessed at enrolment (between Day -30 and Day -10) and at preoperative admission after intake of the allocated nutrition (Day -1) in all patients treated at Lausanne, CHUV.

Insel Gruppe AG, University Hospital Bern

Hôpital Riviera-Chablais, Vaud-Valais

Centre Hospitalier Universitaire Vaudois

MD, Principal Investigator

Prostatic Neoplasms

Prolapse

Pelvic Organ Prolapse

Urinary Retention

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases, Male

Prostatic Diseases

Pathological Conditions, Anatomical

Urination Disorders

Kenneth Peters, MD

The purpose of initiating the Urology Database is to evaluate the outcomes of urology procedures and medical management to enhance the care and treatment of urology patients.

The current study population will include all patients having had a radical prostatectomy for the treatment of prostate cancer, surgical prolapse repair as well as patients having had InterStim sacral nerve stimulator implantation. The database will house data extracted from the medical records. Patient demographics, and preoperative, intra-operative, postoperative, and follow-up clinical data will be collected.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)	NCT05726786	Bladder Cancer Interstitial Cy... Painful Bladder... Neurogenic Blad... Hemorrhagic Cys... Endometriosis Bladder Disease	Immunonutrition	18 Years -	Centre Hospitalier Universitaire Vaudois
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)	NCT05726786	Bladder Cancer Interstitial Cy... Painful Bladder... Neurogenic Blad... Hemorrhagic Cys... Endometriosis Bladder Disease	Immunonutrition	18 Years -	Centre Hospitalier Universitaire Vaudois
Urology Database to Evaluate Clinical Information and Improve Patient Care.	NCT00376298	Incontinence Prostate Cancer Interstitial Cy... Urinary Retenti... Pelvic Organ Pr...		18 Years -	William Beaumont Hospitals
Urology Database to Evaluate Clinical Information and Improve Patient Care.	NCT00376298	Incontinence Prostate Cancer Interstitial Cy... Urinary Retenti... Pelvic Organ Pr...		18 Years -	William Beaumont Hospitals

Spots Global Cancer Trial Database for interstitial cystitis